Here, blood samples from 1075 adult AML patients were subjected to error-corrected NGS-based MRD assessment using a gene panel that included NPM1, FLT3-ITD, IDH1, IDH2, and Kit. The primary finding from the study was that patients with residual NPM1 and/or FLT3-ITD variants prior to allo HCT (AR > 0.01%) had higher relapse rates (68% vs. 21%; P < 0.001) and poorer 3-year survival (39% vs. 63%; P < 0.001) compared to MRD- patients. This evidence concerns the gene IDH1 and acute myeloid leukemia.